Competing risks of monomorphic vs. non-monomorphic ventricular arrhythmias in primary prevention implantable cardioverter–defibrillator recipients: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) study
Europace · 2024
DOI: 10.1093/europace/euae127 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Europace, 2024. Verfasst von Larisa G Tereshchenko und 14 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave, JJN3-01, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Tachycardia, Ventricular, Primary Prevention, Ventricular Fibrillation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: American Heart Association, NHLBI NIH HHS, American Heart Association-American Stroke Association.
Abstract (Originalsprache)
Aims
Ablation of monomorphic ventricular tachycardia (MMVT) has been shown to reduce shock frequency and improve survival. We aimed to compare cause-specific risk factors for MMVT and polymorphic ventricular tachycardia (PVT)/ventricular fibrillation (VF) and to develop predictive models. Methods and results The multicentre retrospective cohort study included 2668 patients (age 63.1 ± 13.0 years; 23% female; 78% white; 43% non-ischaemic cardiomyopathy; left ventricular ejection fraction 28.2 ± 11.1%). Cox models were adjusted for demographic characteristics, heart failure severity and treatment, device programming, and electrocardiogram metrics. Global electrical heterogeneity was measured by spatial QRS-T angle (QRSTa), spatial ventricular gradient elevation (SVGel), azimuth, magnitude (SVGmag), and sum absolute QRST integral (SAIQRST). We compared the out-of-sample performance of the lasso and elastic net for Cox proportional hazards and the Fine–Gray competing risk model. During a median follow-up of 4 years, 359 patients experienced their first sustained MMVT with appropriate implantable cardioverter–defibrillator (ICD) therapy, and 129 patients had their first PVT/VF with appropriate ICD shock. The risk of MMVT was associated with wider QRSTa [hazard ratio (HR) 1.16; 95% confidence interval (CI) 1.01–1.34], larger SVGel (HR 1.17; 95% CI 1.05–1.30), and smaller SVGmag (HR 0.74; 95% CI 0.63–0.86) and SAIQRST (HR 0.84; 95% CI 0.71–0.99). The best-performing 3-year competing risk Fine–Gray model for MMVT [time-dependent area under the receiver operating characteristic curve (ROC(t)AUC) 0.728; 95% CI 0.668–0.788] identified high-risk (> 50%) patients with 75% sensitivity and 65% specificity, and PVT/VF prediction model had ROC(t)AUC 0.915 (95% CI 0.868–0.962), both satisfactory calibration.
Conclusion
We developed and validated models to predict the competing risks of MMVT or PVT/VF that could inform procedural planning and future randomized controlled trials of prophylactic ventricular tachycardia ablation. Clinical Trial Registration URL:www.clinicaltrials.gov Unique identifier:NCT03210883.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave, JJN3-01, Cleveland, OH, USA.
- Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
- Department of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
- Department of Cardiovascular Medicine, University of Colorado, Aurora, CO, USA.
- Department of Cardiovascular Medicine, Stanford University, Palo Alto, CA, USA.
- Department of Cardiovascular Medicine, Cedars-Sinai Health System, Los Angeles, CA, USA.
ORCID-Profile: Larisa G Tereshchenko, Christine Tompkins, Albert J Rogers, Ashkan Ehdaie, Charles A Henrikson, Shivangi Kewalramani, Michael W Kattan, Pasquale Santangeli, Samir R Kapadia, Sanjiv M Narayan, Sumeet S Chugh
Förderung
- American Heart Association
- NHLBI NIH HHS
- American Heart Association-American Stroke Association
- NIH roadmap for Medical Research
- Clinical and Translational Science Collaborative of Cleveland
- NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Tereshchenko, L. G., Waks, J. W., Tompkins, C., Rogers, A. J., Ehdaie, A., Henrikson, C. A., Dalouk, K., Raitt, M., Kewalramani, S., Kattan, M. W., Santangeli, P., Wilkoff, B. W., Kapadia, S. R., Narayan, S. M., & Chugh, S. S. (2024). Competing risks of monomorphic vs. non-monomorphic ventricular arrhythmias in primary prevention implantable cardioverter–defibrillator recipients: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) study. Europace. https://doi.org/10.1093/europace/euae127
Vancouver
Tereshchenko LG, Waks JW, Tompkins C, Rogers AJ, Ehdaie A, Henrikson CA, et al. Competing risks of monomorphic vs. non-monomorphic ventricular arrhythmias in primary prevention implantable cardioverter–defibrillator recipients: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) study. Europace. 2024. doi:10.1093/europace/euae127
BibTeX
@article{Tereshchenko2024,
author = {Tereshchenko, Larisa G and Waks, Jonathan W and Tompkins, Christine and Rogers, Albert J and Ehdaie, Ashkan and Henrikson, Charles A and Dalouk, Khidir and Raitt, Merritt and Kewalramani, Shivangi and Kattan, Michael W and Santangeli, Pasquale and Wilkoff, Bruce W and Kapadia, Samir R and Narayan, Sanjiv M and Chugh, Sumeet S},
title = {Competing risks of monomorphic vs. non-monomorphic ventricular arrhythmias in primary prevention implantable cardioverter–defibrillator recipients: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) study},
journal = {Europace},
year = {2024},
doi = {10.1093/europace/euae127}
}
EUVIMED